Tedisamil
From Self-sufficiency
| File:Tedisamil.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] | |
| Identifiers | |
| CAS Number | 90961-53-8 |
| ATC code | C01BD06 (WHO) |
| PubChem | CID 65825 |
| Chemical data | |
| Formula | C19H32N2 |
| Molar mass | 288.470 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Tedisamil (planned trade name Pulzium) is an investigational class III antiarrhythmic for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.
On April 25, 2007, Solvay submitted a New Drug Application for tedisamil, and on December 12, 2007, the Cardio-Renal Advisory Committee of the FDA voted against approval of tedisamil, at this time, requesting that Solvay Pharmaceuticals provides additional information to the FDA.[1]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Potassium channel blockers
- Nitrogen heterocycles
- Cardiovascular system drug stubs
